A carregar...
A Phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors
BACKGROUND: Carboxyamido-triazole (CAI) is a calcium influx inhibitor with anti-angiogenic and anti-invasive properties and stabilizes tumor progression in patients. We hypothesized daily oral micronized CAI with q3 week paclitaxel would be well-tolerated and active. RESULTS: Twenty-nine heavily pre...
Na minha lista:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2009
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3104675/ https://ncbi.nlm.nih.gov/pubmed/19738417 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|